Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Brief Reports

Pancreatic Elastase-1 in Stools, a Marker of Exocrine Pancreas Function, Correlates With Both Residual β-Cell Secretion and Metabolic Control in Type 1 Diabetic Subjects

  1. Franco Cavalot, MD1,
  2. Katia Bonomo, MD1,
  3. Paolo Perna, MD1,
  4. Elisa Bacillo, PHD2,
  5. Paola Salacone, MD2,
  6. Monica Gallo, MD2,
  7. Luigi Mattiello, MS1,
  8. Mariella Trovati, MD1 and
  9. Ezio Gaia, MD2
  1. 1Diabetes Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Gonzaga Hospital, Turin, Italy
  2. 2Gastroenterology Unit, Department of Internal Medicine, San Luigi Gonzaga Hospital, Turin, Italy
  1. Address correspondence and reprint requests to Prof. Mariella Trovati, MD, University of Turin, San Luigi Gonzaga Hospital, Department of Clinical and Biological Sciences, Diabetes Unit, 10043 Orbassano (TO), Turin, Italy. E-mail: mariella.trovati{at}unito.it
Diabetes Care 2004 Aug; 27(8): 2052-2054. https://doi.org/10.2337/diacare.27.8.2052
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading
  • PE-1, pancreatic elastase-1

Strong relationships exist between endocrine and exocrine pancreas via the islet-acinar portal system, which allows the modulation of pancreatic acinar cells by endopancreatic hormones. In particular, insulin stimulates pancreatic protein synthesis, increases amylase protein and mRNA content, and enhances both pancreatic secretory response to colecystokinin and colecystokinin receptors (1).

In type 1 diabetic patients, a reduction of pancreas function correlating with residual β-cell secretion was described ∼25 years ago with invasive tests (2). An easier evaluation of pancreatic function is now made possible with pancreatic elastase-1 (PE-1) dosage in stools, which shows good correlation with the gold standard of the secretin-cerulein test, is simple to perform, and has an acceptable cost (3,4). In type 1 diabetes, low PE-1 concentrations in stools correlate to poor blood glucose control (5,6). It is not known whether PE-1 correlates to residual β-cell function, which deeply influences metabolic control.

The aim of this study was to evaluate the relationship of PE-1 in stools with both residual β-cell function and glycemic control in type 1 diabetic patients.

RESEARCH DESIGN AND METHODS

We studied 37 consecutive type 1 diabetic patients and performed follow-up at the outpatient clinic of our diabetes unit (16 men and 21 women, aged 34 ± 2 years [mean ± SE]). Diabetes duration was 10.4 ± 1.3 years, BMI 23.9 ± 0.6 kg/m2, caloric intake 2,047 ± 71 kcal/day, fasting plasma glucose 8.76 ± 0.40 mmol/l, C-peptide (radioimmunoassay kit; Adaltis Italia, Bologna, Italy) 0.30 ± 0.07 ng/ml, and HbA1c (high-performance liquid chromatography method, Variant II; BioRad, Milan, Italy) 8.1 ± 0.24%. A total of 20 healthy subjects, matched for age, sex, BMI, and daily caloric intake, were used as control subjects (Table 1). Patients were on steady metabolic control, presented a stable body weight in the previous 6 months, did not report a history or symptoms of gastrointestinal disease, and tested negative for antibodies to gliadin and endomysium. They were on a normocaloric diet with a carbohydrate content accounting for 55–60% of calories, with restriction of simple sugars, a protein content of 1 g/kg body wt, and a lipid content of ∼25–30% of total calories. Subjects received three premeal rapid insulin injections and one bedtime intermediate insulin injection. Two patients were macroalbuminuric (albumin excretion rate >200 μg/min), and six were microalbuminuric (albumin excretion rate between 20 and 200 μg/min); seven subjects had background and two had preproliferative retinopathy.

PE-1 concentrations in stools were determined by enzyme-linked immunosorbent assay (ScheBo Pancreatic Elastase 1 ELISA kit; ScheBo-Tech, Giessen, Germany; intra-assay and interassay coefficients of variation [CVs] 5.8 and 7.7%, respectively). In patients with chronic pancreatitis, the cutoff at 200 μg/g stools shows 100% sensitivity for moderate and severe pancreatic insufficiency, while for patients with exocrine pancreatic insufficiency of any kind, both sensitivity and specificity are 93% (4). Individual daily variations of PE-1 concentrations are very low (mean CV 15%) (4). PE-1 values are not affected by gastric resection, malabsorption, alteration of gastric motility, and therapy with exogenous enzymes (3).

RESULTS

Results have been evaluated by the Mann-Whitney nonparametric test for unpaired data and by linear and multiple regression analyses utilizing StatView software.

PE-1 values in stools in type 1 diabetic patients were significantly lower than in the 20 control subjects (i.e., 263 ± 30 vs. 438 ± 38 μg/g stools; P = 0.0004; 21 of 37 patients had PE-1 values below the lower limit of normal). Sex did not influence PE-1 (men 241 ± 37, women 291 ± 50 μg/g stools; P = NS). PE-1 was correlated to C-peptide (r = 0.565; P = 0.0003) (Fig. 1A). All but one patient with PE-1 <200 μg/g stools had C-peptide ≤0.5 ng/ml. On the contrary, 7 of 30 patients with C-peptide ≤0.5 ng/ml had PE-1 in the normal range. In patients with C-peptide ≤0.5 ng/ml, PE-1 values were ∼50% compared with those in patients with C-peptide >0.5 ng/ml (211 ± 29 vs. 424 ± 62 μg/g stools; P = 0.0044). PE-1 values in patients with C-peptide >0.5 ng/ml were similar to those measured in control subjects (424 ± 62 and 438 ± 38 μg/g stools, respectively; P = NS).

PE-1 was inversely correlated to HbA1c (r = −0.519; P = 0.0001) (Fig. 1B). In patients with HbA1c >8% (cutoff value of bad glycemic control), PE-1 was lower than in those with HbA1c ≤8% (175 ± 26 vs. 346 ± 46 μg/g stools; P = 0.0023). Among patients with HbA1c >8.0%, 14 of 19 had PE-1 <200 μg/g stools compared with 9 of 18 with HbA1c ≤8.0%. HbA1c correlated to C-peptide (r = −0.350; P = 0.033) and diabetes duration (r = 0.450; P = 0.0045).

PE-1 was inversely correlated to diabetes duration (r = −0.470; P = 0.0032) (Fig. 1C). All subjects with diabetes duration >15 years had PE-1 <200 μg/g stools. Also, C-peptide showed an inverse relationship with diabetes duration (r = −0.455; P = 0.0049). Subjects with C-peptide >0.5 ng/ml had shorter diabetes duration than subjects with C-peptide ≤0.5 ng/ml (4.2 ± 1.3 vs. 12.4 ± 1.5 years, respectively; P = 0.0018). Furthermore, only two patients with diabetes duration >5 years presented C-peptide >0.5 ng/ml.

PE-1 values <100 μg/g stools, a marker of a very severe impairment of exocrine pancreas function, were found in four subjects, all with C-peptide ≤0.5 ng/ml and HbA1c >8.0%, three of whom had a diabetes duration >15 years. We measured a fecal fat excretion ≥6 g/day (i.e., over the threshold for steatorrhea) in all of these subjects.

PE-1 was not related to BMI (r = 0.252; P = NS), daily insulin dose (r = 0.233; P = NS), daily insulin dose per kilogram body weight (r = 0.220; P = NS), daily caloric intake (r = 0.085; P = NS), daily urea nitrogen excretion (r = 0.038; P = NS), and albumin excretion rate (r = 0.220; P = NS).

By multiple regression analysis, when PE-1 was considered the independent variable, C-peptide and HbA1c remained significantly correlated to PE-1 (standard coefficient 0.398; P = 0.0134 and standard coefficient −0.331; P = 0.041, respectively), while BMI and diabetes duration did not (Table 2).

CONCLUSIONS

PE-1 concentrations in stools, a reliable marker of exocrine pancreas function, are independently correlated to both glycemic control and residual β-cell function in type 1 diabetic patients, suggesting that also at low levels of β-cell function, residual insulin secretion is important in maintaining exocrine pancreas activity. Furthermore, since patients with C-peptide >0.5 ng/ml showed PE-1 values in stools similar to control subjects, our study suggests that this level could be considered the cutoff point over which endocrine pancreatic function does not impair the exocrine-one. On the other hand, the occurrence of normal PE-1 values in a few patients with C-peptide ≤0.5 ng/ml suggests that insulin secretion is not the only determinant of PE-1 concentrations in stools in type 1 diabetic subjects.

The observation that a small residual insulin secretion modulates exocrine pancreatic function, even in the presence of exogenous insulin treatment, is explained by the fact that the concentrations of insulin needed to exert local effects on acinar cells are much higher than those reached by subcutaneous insulin administration. Insulin concentrations physiologically measured in the immediate periphery of islet cells are two to three orders of magnitude higher than usual circulating values (7). PE-1 concentrations in stools also correlated to glycemic control when residual β-cell secretion was taken into account. The occurrence of glucose toxicity at the exocrine pancreas level could be supposed, since acute hyperglycemia at 15 mmol/l during a hyperglycemic clamp inhibits both basal and low-dose colecystokinin-stimulated exocrine pancreas secretion (8).

The observation that eight patients presented low PE-1 concentrations despite good glycemic control and a relatively short diabetes duration is explained by the fact that seven of eight patients had C-peptide values ≤0.5 ng/ml and five of eight had ≤0.1 ng/ml. Thus, a good glycemic control does not offset the effects of insulin deficiency. Since the correlation of diabetes duration with PE-1 disappears when insulin secretion and glycemic control are taken into account, we suppose that the influence of diabetes duration on PE-1 is attributable to the progressive reduction of β-cell function with time and to the consequent impairment of blood glucose control.

The clinical meaning of our results could also be interpreted in light of our unpublished observation that PE-1 values correlate with fecal fat excretion. In this light, it is not surprising that patients with a PE-1 value <100 μg/g stools presented steatorrhea.

In conclusion, this study shows for the first time that both residual insulin secretion and glycemic control play relevant and independent effects on exocrine pancreatic function in type 1 diabetic patients and confirms the frequent occurrence of a asymptomatic exocrine pancreas deficiency in these patients.

Figure 1—
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1—

A: Linear regression plot of PE-1 in stools versus C-peptide in 37 type 1 diabetic subjects. PE-1 and C-peptide are significantly correlated (r = 0.565; P = 0.0003) The dotted lines identify the subjects with C-peptide <0.5 ng/ml and PE-1 <200 μg/g stools. B: Linear regression plot of PE-1 in stools versus HbA1c are significantly correlated (r = −0.519; P = 0.0001). The dotted lines identify subjects with HbA1c >8.0% and PE-1 <200 μ/g stools. C: Linear regression plot of PE-1 in stools versus duration of type 1 diabetes. PE-1 and diabetes duration are significantly correlated (r = −0.470; P = 0.0032). The dotted lines identify subjects with diabetes duration >15 years and PE-1 <200 μg/g stools.

View this table:
  • View inline
  • View popup
Table 1—

Features of the subjects investigated

View this table:
  • View inline
  • View popup
Table 2—

Multiple regression analysis with PE-1 in stools as the dependent variable

Footnotes

    • Accepted May 8, 2004.
    • Received December 5, 2003.
  • DIABETES CARE

References

  1. ↵
    Williams JA, Golfine ID: The insulin-pancreatic acinar axis. Diabetes 34:980–986, 1985
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Frier BM, Faber OK, Binder C, Elliott HL: The effect of residual insulin secretion on exocrine pancreas function in juvenile-onset diabetes mellitus. Diabetologia 14:301–304, 1978
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Dominguez-Muñoz JE, Hieronymus C, Sauerbruch T, Malfertheiner P: Fecal elastase test: evaluation of a new noninvasive pancreatic function test. Am J Gastroenterol 90:1834–1837, 1995
    OpenUrlPubMedWeb of Science
  4. ↵
    Loser C, Mollegaard A, Folsch UR: Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut 39:580–586, 1996
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Icks A, Haasteert B, Giani G, Rathmann W: Low fecal elastase-1 in type 1 diabetes mellitus. Z Gastroenterol 39:823–830, 2001
    OpenUrlCrossRefPubMed
  6. ↵
    Hardt PD, Krauss A, Brets L, Porsch-Ozcurumez M, Schnell-Kretschmer H, Maser E, Bretzel RG, Zekhorn T, Klor HU: Pancreatic exocrine function in patients with type 1 and type 2 diabetes mellitus. Acta Diabetologica 37:105–110, 2000
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Saito A, Williams JA, Kanno T: Potentiation of cholecystokinin-induced exocrine secretion by both exogenous and endogenous insulin in isolated and perfused rat pancreata. J Clin Invest 65:777–782, 1980
  8. ↵
    Lam WF, Gielkens HA, Coenrad M, Souverijn JH, Lamers CB, Masclee AA: Effect of glucose on basal and colecystokinin-stimulated exocrine pancreatic secretion in humans. Pancreas 18:252–258, 1999
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Diabetes Care: 27 (8)

In this Issue

August 2004, 27(8)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pancreatic Elastase-1 in Stools, a Marker of Exocrine Pancreas Function, Correlates With Both Residual β-Cell Secretion and Metabolic Control in Type 1 Diabetic Subjects
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pancreatic Elastase-1 in Stools, a Marker of Exocrine Pancreas Function, Correlates With Both Residual β-Cell Secretion and Metabolic Control in Type 1 Diabetic Subjects
Franco Cavalot, Katia Bonomo, Paolo Perna, Elisa Bacillo, Paola Salacone, Monica Gallo, Luigi Mattiello, Mariella Trovati, Ezio Gaia
Diabetes Care Aug 2004, 27 (8) 2052-2054; DOI: 10.2337/diacare.27.8.2052

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Pancreatic Elastase-1 in Stools, a Marker of Exocrine Pancreas Function, Correlates With Both Residual β-Cell Secretion and Metabolic Control in Type 1 Diabetic Subjects
Franco Cavalot, Katia Bonomo, Paolo Perna, Elisa Bacillo, Paola Salacone, Monica Gallo, Luigi Mattiello, Mariella Trovati, Ezio Gaia
Diabetes Care Aug 2004, 27 (8) 2052-2054; DOI: 10.2337/diacare.27.8.2052
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • High Incidence of Type 2 Diabetes in Peroxisome Proliferator–Activated Receptor γ2 Pro12Ala Carriers Exposed to a High Chronic Intake of Trans Fatty Acids and Saturated Fatty Acids
  • Combination Therapy With Fenofibrate and Rosiglitazone Paradoxically Lowers Serum HDL Cholesterol
  • β-Cell Transplantation Restores Metabolic Control and Quality of Life in a Patient With Subcutaneous Insulin Resistance
Show more Brief Reports

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.